Diagnostic company LipoScience announced a new agreement to place the Vantera Clinical Analyzer within Scripps Health facilities, marking the first placement of the device in the state of California. The agreement makes NMR lipoprotein testing on the analyzer available to Scripps Health customers.
The Vantera Clinical Analyzer is able to identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. This analysis provides the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information from a simple blood test. An integral component of the company's NMR LipoProfile test, LDL-P is the first FDA-cleared assay on the Vantera Clinical Analyzer.
Adopting and decentralizing the Vantera Clinical Analyzer into clinical labs will ultimately provide broad access to the NMR LipoProfile test, also reducing sample processing turnaround time and providing value to physicians who are focused on delivering quality patient care and personalized cardiovascular disease (NYSE:CVD) management. More than 10 million NMR LipoProfile tests have been ordered to date.
"LDL particle number is increasingly understood to be a more clinically reliable measure of LDL, and we believe it should be a key component of cardiovascular disease management," said Michael Quigley, M.D., medical director of Scripps Medical Laboratory. "By placing the Vantera Clinical Analyzer within our facilities, Scripps Health will be able to help physicians devise personalized cardiovascular risk-reduction strategies tailored to individual patients' needs."
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com